An interventional study of Web-Based Ovarian Cancer Awareness Education and General Reproductive Health Information in Ovarian Cancer, sponsored by Ege University. Not yet recruiting. Open to female participants aged 20 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Ege University · Not applicable, Interventional, and Other
This randomized controlled study will evaluate the effects of web-based ovarian cancer awareness education on women's awareness of ovarian cancer, health beliefs, and risk-reducing behaviors.
Participants will be randomly assigned to an intervention group or a control group. The intervention group will receive web-based education developed using the Health Belief Model. The educational modules will cover female reproductive organs and cancers, ovarian cancer, symptoms, diagnosis and treatment, risk factors, risk-reducing behaviors, and barriers to taking action.
The groups will be compared using assessments conducted before the education and three months after its completion to determine whether the education improves ovarian cancer awareness, health beliefs, and risk-reducing behaviors.
This study is a two-arm, parallel-group randomized controlled trial with baseline and follow-up assessments. It will evaluate the effects of a web-based ovarian cancer awareness education program based on the Health Belief Model on women's ovarian cancer awareness, health beliefs, and risk-reducing behaviors.
The study will recruit women attending the gynecology outpatient clinic at Izmir University of Health Sciences Tepecik Training and Research Hospital, Turkey. A total of 80 participants will be allocated to the intervention and control groups, with 40 participants in each group.
After informed consent and baseline assessments, participants will be randomly assigned in a 1:1 ratio using computer-generated simple randomization. Randomization will be performed by a researcher other than the researcher delivering the intervention. Participants will not be told whether their assigned group is designated as the intervention or control group. All participants will receive information about the educational website. However, because access to the website will be provided at different times, participant masking cannot be assured. The researcher performing the statistical analysis will receive data with the groups coded as A and B, and the meaning of these codes will not be disclosed until the analysis is completed.
Participants in the intervention group will receive individual usernames and passwords to access the educational website. They will be asked to complete seven sequential modules within four weeks. The modules will cover female reproductive organs, gynecological cancers, ovarian cancer and its risk factors, symptoms, diagnosis and treatment, protective factors and risk-reducing behaviors, and perceived barriers and possible solutions.
The educational program will address perceived susceptibility, perceived severity, perceived benefits, perceived barriers, self-efficacy, and cues to action within the Health Belief Model. Participants will complete each module before proceeding to the next. Module completion will be monitored through the website's administrative panel. An ovarian cancer awareness education guide will also be sent through WhatsApp. Weekly messages and telephone contact will support completion of the program.
Participants in the control group will continue to receive routine gynecological care, including clinical assessment, counseling, and diagnostic or treatment services as needed. To maintain contact and reduce loss to follow-up, they will receive weekly educational messages through WhatsApp about general reproductive health topics other than ovarian cancer. They will not have access to the ovarian cancer educational website during the follow-up period. After their final assessment, they will receive the ovarian cancer education guide and access to the website.
Both groups will complete assessments at baseline and three months after the end of the four-week education period, approximately four months after baseline. The control group will follow the same assessment schedule. Data collection instruments will include a participant information form, the Ovarian Cancer Awareness Scale, the Cancer Screening Perception Scale, and the Ovarian Cancer Risk-Reducing Behaviors Form. Website usability will be evaluated using the System Usability Scale among participants who use the educational platform.
The analysis will examine changes over time and differences between the intervention and control groups in ovarian cancer awareness, health beliefs, and risk-reducing behaviors.
2,757 studies on the registry are indexed under Ovarian Neoplasms; 735 are open to participants now.
This study's planned enrollment of 82 is above the median of 59 across 2,075 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Ege University is the lead sponsor of 375 studies on the registry; 47 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive a four-week web-based ovarian cancer awareness education program based on the Health Belief Model. Seven modules will be accessed sequentially using individual usernames and passwords. An ovarian cancer awareness education guide will also be provided through WhatsApp. Weekly messages and telephone contact will support completion, and module completion will be monitored through the website's administrative panel. Participants will continue to receive routine gynecological care.
Behavioral: Web-Based Ovarian Cancer Awareness Education
Participants will receive routine gynecological care and weekly WhatsApp messages about general reproductive health topics unrelated to ovarian cancer. These messages will maintain contact and help reduce loss to follow-up. Participants will not have access to the ovarian cancer educational website during the follow-up period. After the final assessment, they will receive the ovarian cancer awareness education guide and access to the website.
Behavioral: General Reproductive Health Information
A four-week web-based education program based on the Health Belief Model, comprising seven sequential modules on female reproductive organs, gynecological cancers, ovarian cancer and risk factors, symptoms, diagnosis and treatment, protective factors and risk-reducing behaviors, and perceived barriers and solutions. Participants will access the website using individual usernames and passwords and complete each module before proceeding to the next. An ovarian cancer awareness education guide will be provided through WhatsApp. Weekly messages and telephone contact will support program completion. Module completion will be monitored through the website's administrative panel.
Weekly WhatsApp messages providing general reproductive health information unrelated to ovarian cancer, in addition to routine gynecological care. The messages are intended to maintain contact and reduce loss to follow-up. Participants will not receive ovarian cancer education or access to the educational website until after the final assessment.
Change in Ovarian Cancer Symptom Recall Score
Change from baseline in the symptom recall score of the Turkish version of the Ovarian Cancer Awareness Scale. Participants will list ovarian cancer symptoms in an open-ended question. Each correctly recalled symptom will receive 1 point, with scores ranging from 0 to 10. Higher scores indicate greater awareness of ovarian cancer symptoms. Changes will be compared between the intervention and control groups.
Time frame: Baseline and three months after completion of the four-week education period (approximately four months after baseline).
Change in Ovarian Cancer Symptom Recognition Score
Change from baseline in the symptom recognition score of the Turkish version of the Ovarian Cancer Awareness Scale. Participants will identify whether each of 10 listed symptoms could be a symptom of ovarian cancer, using "yes," "no," or "don't know" responses. Each "yes" response will receive 1 point; "no" and "don't know" responses will receive 0 points. Scores range from 0 to 10, with higher scores indicating greater symptom recognition. Changes will be compared between the intervention and control groups.
Time frame: Baseline and three months after completion of the four-week education period (approximately four months after baseline).
Change in Ovarian Cancer Risk Factor Recall Score
Change from baseline in the risk factor recall score of the Turkish version of the Ovarian Cancer Awareness Scale. Participants will list ovarian cancer risk factors in an open-ended question. Each correctly recalled risk factor will receive 1 point, with scores ranging from 0 to 12. Higher scores indicate greater awareness of ovarian cancer risk factors. Changes will be compared between the intervention and control groups.
Time frame: Baseline and three months after completion of the four-week education period (approximately four months after baseline).
Change in Ovarian Cancer Risk Factor Awareness Score
Change from baseline in the risk factor awareness score of the Turkish version of the Ovarian Cancer Awareness Scale. This section includes 12 items rated on a five-point Likert scale, from 1 (strongly disagree) to 5 (strongly agree). Scores range from 12 to 60. Higher scores indicate greater awareness of ovarian cancer risk factors. Changes will be compared between the intervention and control groups.
Time frame: Baseline and three months after completion of the four-week education period (approximately four months after baseline).
Change in Perceived Severity Subscale Score of the Cancer Screening Perception Scale
Change from baseline in the perceived severity subscale score of the Turkish version of the Cancer Screening Perception Scale. This subscale consists of four items rated on a six-point Likert scale. Scores range from 4 to 24. According to the scoring description, higher scores indicate lower perceived severity. Changes will be compared between the intervention and control groups.
Time frame: Baseline and three months after completion of the four-week education period (approximately four months after baseline).
Change in Perceived Susceptibility Subscale Score of the Cancer Screening Perception Scale
Change from baseline in the perceived susceptibility subscale score of the Turkish version of the Cancer Screening Perception Scale. This subscale consists of five items rated on a six-point Likert scale. Scores range from 5 to 30. Higher scores indicate lower perceived susceptibility. Changes will be compared between the intervention and control groups.
Time frame: Baseline and three months after completion of the four-week education period (approximately four months after baseline).
Change in Perceived Benefits Subscale Score of the Cancer Screening Perception Scale
Change from baseline in the perceived benefits subscale score of the Turkish version of the Cancer Screening Perception Scale. This subscale consists of six items rated on a six-point Likert scale. Scores range from 6 to 36. Higher scores indicate greater perceived benefits of cancer screening tests. Changes will be compared between the intervention and control groups.
Time frame: Baseline and three months after completion of the four-week education period (approximately four months after baseline).
Change in Perceived Barriers Subscale Score of the Cancer Screening Perception Scale
Change from baseline in the perceived barriers subscale score of the Turkish version of the Cancer Screening Perception Scale. This subscale consists of five items rated on a six-point Likert scale. Scores range from 5 to 30. Higher scores indicate greater perceived barriers to cancer screening. Changes will be compared between the intervention and control groups.
Time frame: Baseline and three months after completion of the four-week education period (approximately four months after baseline).
Change in Cues to Action Subscale Score of the Cancer Screening Perception Scale
Change from baseline in the cues to action subscale score of the Turkish version of the Cancer Screening Perception Scale. This subscale consists of six items rated on a six-point Likert scale. Scores range from 6 to 36. According to the scoring description, higher scores indicate a greater number of self-reported symptoms that may prompt action. Changes will be compared between the intervention and control groups.
Time frame: Baseline and three months after completion of the four-week education period (approximately four months after baseline).
Change in Item-Level Responses on the Ovarian Cancer Risk-Reducing Behavior Awareness Form
A researcher-developed 15-item form will assess self-reported lifestyle behaviors, symptom-related healthcare seeking, and intentions regarding physician-recommended diagnostic or preventive procedures. Each item has five response categories: never, rarely, sometimes, often, and always. For each item, the percentage of participants selecting each response category will be calculated at baseline and follow-up, and changes will be compared between groups. Items will be analyzed separately; no total score will be calculated. More frequent genital talc use will not be interpreted as a favorable change.
Time frame: Baseline and three months after completion of the four-week education period (approximately four months after baseline).
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
Of 251 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 4 months is below that.
Counting every sponsor, half of 257 studies reached it within 48 months; a quarter within 24 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.